A Research Opportunity Announcement (ROA) is a public document that announces the availability of an Other Transaction (OT). It provides the initiative’s purpose, type of award, instructions on how to apply, due date for proposals or applications, and research opportunity number.
Information about Other Transactions can be found on the NIH Grants & Funding website.
File
Title | OTA Number | Purpose | OTA Category | Contact |
---|---|---|---|---|
HEAL Initiative: EPPIC-Net Pain Research Asset Application (OT2) | OTA-22-002 | The purpose of this research opportunity announcement (ROA) is to invite Stage 1 preliminary applications for submission of therapeutics, including but not limited to, drugs, biologics, and devices as well as biomarkers (termed assets) for study in the HEAL Initiative’s EPPIC-Net. | HEAL/EPPIC-Net | Barbara Karp, MD |
HEAL Initiative: EPPIC-Net Pain Research Asset Application- Dossier | OTA-23-005 | The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Dossier applications for submission of assets that have successfully passed Stage 1 preliminary application review. EPPIC-Net applications are reviewed in a three-stage process. applications to Stages 2 & 3 will be by invitation only. | HEAL/EPPIC-Net | Barbara Karp, MD |
HEAL Initiative: EPPIC-Net Pain Research – Application for Clinical Trials and Related activities (OT2) | OTA-23-006 | The purpose of this research opportunity announcement (ROA) is to fund early phase clinical trials of pain therapeutic assets and its related activities. The ROA accepts applications from the EPPIC-Net CCC, working in conjunction with the EPPIC-Net DCC and SCCs, for funding of clinical trial preparatory activities not covered by EPPIC-Net U24 agreements to the CCC, DCC, or Specialized Clinical Centers (Hubs/Spokes), as well as applications for specific clinical trials. | HEAL/EPPIC-Net | Barbara Karp, MD |
StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 2 Protocol Application (OT2) | OTA-24-010 | The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and systems of care for EVT,to be conducted within the StrokeNet Thrombectomy Platform (STEP) within the NIH StrokeNet network. | STEP | Scott Janis, PhD |
StrokeNet Thrombectomy Platform (STEP) – Domain Clinical trials to be conducted in STEP: Stage 1 Preliminary Application (OT2) | OTA-24-009 | The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials that will address the indication expansion of current endovascular therapy (EVT) criteria, concomitant medical therapies added to EVT, novel EVT devices, and(STEP) within the NIH StrokeNet network. | STEP | Scott Janis, PhD |
Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 1 Preliminary Application (OT2) | OTA-24-011 | The purpose of this research opportunity announcement (ROA) is to invite Stage 1 Preliminary Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |
Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 2 Protocol Application (OT2) | OTA-24-012 | The purpose of this research opportunity announcement (ROA) is to invite Stage 2 Protocol Applications for clinical trials of gene-based and gene-targeted therapies for ultra-rare neurological diseases, to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |
OTA-24-013: NeuroNEXT Clinical Trials: Stage 1 Preliminary Application (OT2) | OTA-24-013 | The purpose of this research opportunity announcement (ROA) is to invite applicants to submit Stage 1 Preliminary Applications of assets proposed for exploratory clinical trials or biomarker studies focused on neurological diseases to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |
OTA-24-014: NeuroNEXT Clinical Trials: Stage 2 Protocol Application (OT2) | OTA-24-014 | The purpose of this research opportunity announcement (ROA) is to invite applicants to submit Stage 2 Protocol Applications for exploratory clinical trials or biomarker studies focused on neurological diseases to be conducted within the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). | NeuroNext | Sophie (Hyun Joo) Cho, MD |